Cargando…

Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele

Combination antiretroviral treatment (cART) has significantly improved the life expectancy of people living with HIV. The life-long nature of cART increases the risk of side effects, which in some cases may have been caused by specific genetic characteristics. Patients treated with atazanavir (ATV)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panagopoulos, Periklis, Maltezos, Efstathios, Hatzakis, Angelos, Paraskevis, Dimitrios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488765/ https://www.ncbi.nlm.nih.gov/pubmed/28790862 http://dx.doi.org/10.2147/PGPM.S107152

Ejemplares similares

Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele
por: Naidoo, Anushka, et al.
Publicado: (2017)

Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis
por: Du, Pengqiang, et al.
Publicado: (2019)

High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece
por: Panagopoulos, P, et al.
Publicado: (2010)

Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia
por: Vardhanabhuti, Saran, et al.
Publicado: (2015)

1572 Impact of Hyperbilirubinemia on Persistence and Adherence of Atazanavir among HIV Patients
por: Rosenblatt, Lisa, et al.
Publicado: (2014)

Analysis of the UGT1A1 Genotype in Hyperbilirubinemia Patients: Differences in Allele Frequency and Distribution
por: Mi, Xiao-xiao, et al.
Publicado: (2019)

Incidence of Atazanavir-associated Hyperbilirubinemia in Korean HIV Patients: 30 Months Follow-up Results in a Population with Low UDP-glucuronosyltransferase1A1*28 Allele Frequency
por: Choe, Pyoeng Gyun, et al.
Publicado: (2010)

Profiling of UGT1A1(*)6, UGT1A1(*)60, UGT1A1(*)93, and UGT1A1(*)28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
por: Amandito, Radhian, et al.
Publicado: (2019)

Association Between Atazanavir‐Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV
por: Li, Michael, et al.
Publicado: (2020)

Clinical significance of the UGT1A1*28 allele detection in HIV-infected patients
por: Kanestri, Veronika, et al.
Publicado: (2014)

Commentary: Profiling of UGT1A1(*)6, UGT1A1(*)60, UGT1A1(*)93, and UGT1A1(*)28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
por: Heydari, Mohammad Reza, et al.
Publicado: (2020)

Drug‐drug interaction of atazanavir on UGT1A1‐mediated glucuronidation of molidustat in human
por: van der Mey, Dorina, et al.
Publicado: (2020)

Genetic Spectrum of UGT1A1 in Korean Patients with Unconjugated Hyperbilirubinemia
por: Kim, Jin Ju, et al.
Publicado: (2020)

Correlations between atazanavir C(trough )and hyperbilirubinemia: a case report
por: Uglietti, Alessia, et al.
Publicado: (2009)

Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor
por: Saif, Muhammad Wasif, et al.
Publicado: (2016)

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
por: Xu, C-F, et al.
Publicado: (2010)

The Effect of UGT1A1 Promoter Polymorphism in the Development of Hyperbilirubinemia and Cholelithiasis in Hemoglobinopathy Patients
por: AlFadhli, Suad, et al.
Publicado: (2013)

Association of Neonatal Hyperbilirubinemia with UGT1A1 Gene Polymorphisms: A Meta-Analysis
por: Yu, Zibi, et al.
Publicado: (2015)

Inflammatory signature of cerebellar neurodegeneration during neonatal hyperbilirubinemia in Ugt1(-/-) mouse model
por: Vodret, Simone, et al.
Publicado: (2017)

Atazanavir-induced unconjugated hyperbilirubinemia prevents vascular hyporeactivity during experimental human endotoxemia
por: Dorresteijn, Mirrin J., et al.
Publicado: (2023)

Association of UGT1A1 Variants and Hyperbilirubinemia in Breast-Fed Full-Term Chinese Infants
por: Zhou, Youyou, et al.
Publicado: (2014)

Glucose induces intestinal human UDP-glucuronosyltransferase (UGT) 1A1 to prevent neonatal hyperbilirubinemia
por: Aoshima, Naoya, et al.
Publicado: (2014)

UGT1A1 gene and neonatal hyperbilirubinemia: a preliminary study from Bengkulu, Indonesia
por: Amandito, Radhian, et al.
Publicado: (2018)

UGT1A1 Genetic Variations and a Haplotype Associated with Neonatal Hyperbilirubinemia in Indonesian Population
por: Wisnumurti, Dewi A., et al.
Publicado: (2018)

The role of UGT1A1 (c.-3279 T > G) gene polymorphisms in neonatal hyperbilirubinemia susceptibility
por: Li, Zijin, et al.
Publicado: (2020)

Low efficacy of recombinant SV40 in Ugt1a1(-/-) mice with severe inherited hyperbilirubinemia
por: Shi, Xiaoxia, et al.
Publicado: (2021)

UGT1A1 variants in Chinese Uighur and Han newborns and its correlation with neonatal hyperbilirubinemia
por: Yang, Hui, et al.
Publicado: (2022)

Comparative evaluation of the performance of the Abbott RealTime HIV-1 assay for measurement of HIV-1 plasma viral load on genetically diverse samples from Greece
por: Katsoulidou, Antigoni, et al.
Publicado: (2011)

Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain
por: Bravo-Gómez, Adrián, et al.
Publicado: (2022)

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
por: Rekić, Dinko, et al.
Publicado: (2012)

Combined Effects of UGT1A1 and SLCO1B1 Variants on Chinese Adult Mild Unconjugated Hyperbilirubinemia
por: Bai, Jie, et al.
Publicado: (2019)

Associations between UGT1A1 and SLCO1B1 polymorphisms and susceptibility to neonatal hyperbilirubinemia in Thai population
por: Atasilp, Chalirmporn, et al.
Publicado: (2022)

Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy
por: Poblete, Daniela, et al.
Publicado: (2021)

Polymorphisms of UGT1A1(*)6, UGT1A1(*)27 & UGT1A1(*)28 in three major ethnic groups from Malaysia
por: Teh, L. K., et al.
Publicado: (2012)

Transmission Dynamics of HIV-1 Drug Resistance among Treatment-Naïve Individuals in Greece: The Added Value of Molecular Epidemiology to Public Health
por: Paraskevis, Dimitrios, et al.
Publicado: (2017)

A novel UGT1A1 gene mutation causing severe unconjugated hyperbilirubinemia: a case report
por: Shi, Xiaoxia, et al.
Publicado: (2019)

Patterns of drug resistance among newly diagnosed HIV-1 infected patients in Greece during the last decade: the crucial role of transmission networks
por: Paraskevis, Dimitrios, et al.
Publicado: (2014)

Immunomodulatory Function of HBeAg Related to Short-Sighted Evolution, Transmissibility, and Clinical Manifestation of Hepatitis B Virus
por: Kramvis, Anna, et al.
Publicado: (2018)

Gilbert or Crigler–Najjar syndrome? Neonatal severe unconjugated hyperbilirubinemia with P364L UGT1A1 homozygosity
por: Cozzi, Laura, et al.
Publicado: (2022)

UGT1A1 mutation association with increased bilirubin levels and severity of unconjugated hyperbilirubinemia in ABO incompatible newborns of China
por: Yang, Hui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q099qdk47j7l6tvih3pps5vf0j